Navigation Links
US Patent Office Issues Patent for VG Life Sciences' Peptide for HIV Treatment
Date:10/31/2013

gnosis and of introducing a treatment regimen into a subject."

John Tynan, VG Life Sciences' President and CEO said, "First, this is a great recognition of Dr. Newell Rogers' hard work and ground breaking research. Second, this reflects our commitment to expand and secure our IP portfolio."

About VG Life Sciences Inc.

Santa Barbara, California-based VG Life Sciences Inc., formerly known as Viral Genetics, is a biotechnology company working on discovering and developing drug therapies for infectious diseases, cancer and many autoimmune diseases. VGLS controls over 50 US and international patents and patents pending protecting its exclusive biotech platform technologies. For more information and upcoming events, visit www.vglifesciences.com or find VG Life Sciences, Inc. on Facebook, Twitter, and LinkedIn.

Safe Harbor Statement and Forward-Looking Statements

 This news release may contain forward-looking statements that involve risks and uncertainties associated with financial projections, milestone timelines, clinical development, regulatory approvals and other risks described by VG Life Sciences from time to time in its periodic reports. None of VG Life Sciences' drug compounds are approved by the US FDA or by any comparable regulatory agencies elsewhere in the world. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by VG Life Sciences or any other person that the objectiv
'/>"/>

SOURCE VG Life Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Enbrel® (etanercept) Patent Issued
2. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
3. Cenestra Health Announces Granting of Broad Patent Covering Proprietary Bioactive Lipid Formulations
4. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
5. Northwest Bio Reaffirms Its Freedom to Operate; Refutes Other Parties Misleading Patent Assertions
6. Bio-AMD, Inc.; DSR Commercial Refinement, Prospective Patent Applications
7. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
8. Arcion Receives Notice of Allowance for US Patent for Novel Topical Lidocaine Formulation for Pain
9. NanoLogix Instructs Third-Party to Prepare US FDA Submittals and is Granted US and Chinese Patents
10. Saladax Biomedical, Inc. Issued Six Patents Containing Broad Claims in the Immunoassay Space
11. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... Nov. 24, 2014  Last week, Representatives ... (D-NC) took a bold bipartisan step on ... the OPEN Act. Original co-sponsors of the legislation ... Act will incentivize drug makers and innovators to ... and pediatric cancers, which opens the door to ...
(Date:11/24/2014)... MD (PRWEB) November 24, 2014 ... underrepresented patient populations into clinical trials at its ... , “Continental was created with the idea ... play a fundamental role in medical advances," said ... Tuskegee syphilis experiment to the immortal cell line ...
(Date:11/23/2014)... November 23, 2014 Apiscent Labs, ... of fine chemical ingredients to the global pharmaceutical ... of its new website, Apiscent.com. , The Apiscent.com ... Labs, clean design, easy navigation, rotating images and ... Labs stand out. , The company’s ...
(Date:11/22/2014)... RURO, Inc., a leading LIMS, ... Limfinity® version 5.1.4. , RURO’s deployment teams have ... ever in RURO’s 8 year history. Many deployments ... Limfinity® version 5.1.4 is the perfect example – ... fixes! , Limfinity® 5.1.4 release highlights – more ...
Breaking Biology Technology:OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3RURO Announces Limfinity® version 5.1.4 2
... 2009A team of Los Alamos researchers led by Victor ... multiple electronsis a real phenomenon in tiny semiconductor crystals ... that mimic carrier multiplication. The research, explained in a ... shows the possibility of solar cells that create more ...
... Personalized Medicine Conference is bringing together the wide variety of stakeholders ... opportunities and challenges facing those involved in the development and realization ... ... 10, 2009 -- Arrowhead,s 2009 Personalized Medicine Conference is ...
... System Will Continue to Fuel Growth and Generate CashNEW YORK, ... Vice President James C. Borel said today he expects DuPont ... share by at least 1 to 2 points in 2009 ... DuPont Agriculture & Nutrition segment an average of at least ...
Cached Biology Technology:Research highlights potential for improved solar cells 2Research highlights potential for improved solar cells 3The Biggest Names in the Field of Personalized Medicine to Speak at Arrowhead's Upcoming 2009 Personalized Medicine Conference 2The Biggest Names in the Field of Personalized Medicine to Speak at Arrowhead's Upcoming 2009 Personalized Medicine Conference 3DuPont Expects Increased Global Seed Corn Share, Continued Agriculture Earnings Growth 2DuPont Expects Increased Global Seed Corn Share, Continued Agriculture Earnings Growth 3DuPont Expects Increased Global Seed Corn Share, Continued Agriculture Earnings Growth 4DuPont Expects Increased Global Seed Corn Share, Continued Agriculture Earnings Growth 5
(Date:11/7/2014)... Auguste, associate professor, biomedical engineering, in the Grove ... New York, have identified a molecule that could ... most aggressive forms of breast cancer. , Triple ... rate owing to aggressive proliferation and metastasis and ... Auguste,s team, discovered the overexpression of intercellular adhesion ...
(Date:11/6/2014)... A groundbreaking paper from a team of Florida State ... how plants could adapt to and survive environmental swings ... in the latest issue of the journal The ... complex of DNA and proteins) is organized in a ... some genes are turned on and others are turned ...
(Date:11/6/2014)... Baltimore, MD, November 6, 2014 - Insilico Medicine, ... in aging and age related diseases announced a ... medicine of cancer, Champions Oncology, Inc (OTC: CSBR). ... genomics for personalized medicine, but Champions Oncology,s TumorGraft ... can validate the chemotherapy regimen experimentally generating vast ...
Breaking Biology News(10 mins):Maize analysis yields whole new world of genetic science 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2
... Academic Affairs John Wiecha, MD, MPH, in the Department ... Health (NIH) American Recovery & Reinvestment Act (ARRA) Challenge ... valued at more than $950,000 will fund a study ... diabetes. The health education will be conducted either ...
... years ago, vertebrates lacked the ability to chew their food. ... a flexible, fused basket of cartilage. This week, an ... the University of Colorado at Boulder published evidence that three ... development of jaws in higher vertebrates. The finding is ...
... adverts, the secret of fertility might not be eternal youth. ... Research at the Consejo Superior de Investigaciones Cientficas in Seville, ... have evolved to protect their seeds. His research is published ... Botany ( http://dx.doi.org/10.1093/aob/mcq160 ). Prof. Herrera said: "No ...
Cached Biology News:Wiecha receives grant to study face-to-face vs. virtual health education for African-American women 2Genetic clues to evolution of jaws in vertebrates unearthed by CU-led team 2
HLA II DG+DR+DP Monoclonal Antibody, Purified, Unconjugated, Clone: IQU9 This antibody is specific for the monomorphic determinant of the HLA Class II beta chains of the human MHC (28 kDa)....
Anti-gp120/160(SIV/mac239) Immunogen: gp120(SIV/mac239) protein (Genebank accession #M33262)...
Phospho-MEF2A(Thr312)...
Tube-O-DIALYZER Floats, small....
Biology Products: